Bayer supporting GARFIELD, an atrial fibrillation registry
This article was originally published in Scrip
Executive Summary
A research grant from Bayer Schering Pharma is supporting GARFIELD (the global anticoagulant registry in the field), the first-ever global atrial fibrillation registry. It will follow, for six years, 50,000 patients from 32 countries who are newly diagnosed with atrial fibrillation. GARFIELD is the first prospective registry in the condition; clinical sites will be selected at random to avoid selection bias, and patients included whether or not they receive anticoagulant therapy. The study is being conducted by the Thrombosis Research Institute, which is affiliated with Queen Mary University of London.
You may also be interested in...
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.
Theravance's Gut-Selective JAK Inhibitor Disappoints In Ulcerative Colitis Study
Top-line results from a Phase IIb study of Theravance’s potential gut-selective JAK inhibitor izencitinib have not matched expectations, and results from a similar early-stage study in Crohn’s disease with the Janssen-partnered candidate are now awaited at the end of the year or in early 2022.